Wu David, Tischler Arthur S, Lloyd Ricardo V, DeLellis Ronald A, de Krijger Ronald, van Nederveen Francien, Nosé Vânia
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Am J Surg Pathol. 2009 Apr;33(4):599-608. doi: 10.1097/PAS.0b013e318190d12e.
Morphologic determination of the malignant potential of adrenal pheochromocytoma is a challenging problem in surgical pathology. A multiparameter Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) was recently developed based on a comprehensive study of a single institutional cohort of 100 cases. Assignment of a PASS was proposed to be useful for identifying pheochromocytomas with potential to metastasize, which defines malignancy according to the current World Health Organization terminology. A PASS is derived by evaluating multiple morphologic parameters to obtain a scaled score based on the summed weighted importance of each. Despite the proposal of this system several years ago, few studies have since examined its robustness and, in particular, the potential for observer variation inherent in the interpretation and assessment of these morphologic criteria. We further examined the utility of PASS by reviewing an independent single institutional cohort of adrenal pheochromocytomas as evaluated by 5 multi-institutional pathologists with at least 10 years experience in endocrine pathology. We found significant interobserver and intraobserver variation in assignment of PASS with variable interpretation of the underlying components. We consequently suggest that PASS requires further refinement and validation. We cannot currently recommend its use for clinical prognostication.
肾上腺嗜铬细胞瘤恶性潜能的形态学判定是外科病理学中一个具有挑战性的问题。基于对一个机构的100例病例的综合研究,最近开发了一种多参数肾上腺嗜铬细胞瘤分级评分系统(PASS)。PASS的赋值被认为有助于识别具有转移潜能的嗜铬细胞瘤,根据世界卫生组织目前的术语,这定义为恶性肿瘤。PASS是通过评估多个形态学参数得出的,根据每个参数的加权重要性总和获得一个分级分数。尽管该系统在几年前就已提出,但此后很少有研究检验其稳健性,特别是这些形态学标准的解释和评估中固有的观察者变异可能性。我们通过回顾一个独立的单一机构的肾上腺嗜铬细胞瘤队列,由5位在内分泌病理学方面至少有10年经验的多机构病理学家进行评估,进一步检验了PASS的实用性。我们发现观察者间和观察者内对PASS赋值存在显著差异,对基础成分的解释也各不相同。因此,我们建议PASS需要进一步完善和验证。目前我们不能推荐将其用于临床预后判断。